Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 11:28 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1585–1608 of 4,175 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control comparison Clear all

Conditions: Vascular Closure, Pacemaker Implantation, Leadless Pacemaker
Interventions: percutaneous suture mediated closure, Figure of Eight Suture; Device
Lead sponsor: University of Massachusetts, Worcester; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Worcester, Massachusetts

Conditions: Body Image, Self Esteem
Interventions: Celebrandome; Behavioral
Lead sponsor: Arizona State University; Other
Eligibility: 11 Years to 16 Years
Enrollment: 154 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Diabetes Mellitus Type 2
Interventions: Metformin, Placebo (matching sitagliptin), Placebo (matching taspoglutide), Sitagliptin, Taspoglutide; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 666 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 64
States / cities: Birmingham, Alabama • Huntsville, Alabama • Tallassee, Alabama + 58 more

Conditions: Facial Dermatoses, Seborrheic Keratoses
Interventions: Pulsed dye laser, Curettage, Electrodesiccation, No treatment; Device · Procedure · Other
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Chronic Obstructive Pulmonary Disease (COPD)
Interventions: Indacaterol 150 μg, Tiotropium 18 μg, Placebo to indacaterol; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 40 Years and older
Enrollment: 1,134 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 61
States / cities: Birmingham, Alabama • Mobile, Alabama • Scottsdale, Arizona + 53 more

Conditions: Reduction in Hypertrophic Skin Scarring
Interventions: EXC 001; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 12
States / cities: Pasadena, California • Whittier, California • Lake Worth, Florida + 7 more

Conditions: Postoperative Pain
Interventions: Pregabalin, Acetaminophen, Placebo 1, Placebo 2; Drug · Other
Lead sponsor: Nevakar, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 87 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020
U.S. locations: 2
States / cities: Pasadena, California • Bellaire, Texas

Conditions: Heart Failure
Interventions: Baxdrostat and dapagliflozin, Placebo and dapagliflozin; Drug · Other
Lead sponsor: AstraZeneca; Industry
Eligibility: 40 Years and older
Enrollment: 11,300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 217
States / cities: Birmingham, Alabama • Centreville, Alabama • Fairhope, Alabama + 188 more

Conditions: Hypertension, Diabetes Mellitus, Type 2
Interventions: Active Control, INV-144; Drug
Lead sponsor: InVasc Therapeutics, Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 88 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 19
States / cities: Garden Grove, California • La Mesa, California • Northridge, California + 15 more

Conditions: Metabolic Syndrome, Protection Against, Diet, Healthy
Interventions: Home-Based Video and Motivational Interviewing Intervention, Read Educate and Develop Youth (READY) Comparison; Behavioral
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 257 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Ametropia
Interventions: enfilcon A, galyfilcon A; Device
Lead sponsor: CooperVision, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012
U.S. locations: 3
States / cities: Pismo Beach, California • San Diego, California • East Lansing, Michigan

Conditions: Glaucoma, Cataract
Interventions: Pred Forte, EconoPred Plus, Prednisolone Acetate; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2011
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Metastatic Breast Cancer
Interventions: Bevacizumab [Avastin], Paclitaxel, Placebo; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 481 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 66
States / cities: Birmingham, Alabama • Tucson, Arizona • Corona, California + 58 more

Conditions: Community Acquired Bacterial Pneumonia
Interventions: Delafloxacin, Moxifloxacin, Linezolid; Drug
Lead sponsor: Melinta Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 25
States / cities: Montgomery, Alabama • Newark, Delaware • Coral Gables, Florida + 21 more

Conditions: Second Trimester Abortion
Interventions: Laminaria, Dilapan-S; Device
Lead sponsor: Planned Parenthood of Greater New York; Other
Eligibility: 18 Years and older · Female only
Enrollment: 180 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: New York, New York

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: insulin degludec, insulin glargine, insulin aspart; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,006 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 66
States / cities: Alexander City, Alabama • Birmingham, Alabama • Goodyear, Arizona + 61 more

Conditions: Seasonal Allergic Rhinitis
Interventions: Fluticasone propionate, Flonase®, Placebo; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 12 Years and older
Enrollment: 1,474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Dry Eye
Interventions: VSJ-110, Placebo; Drug
Lead sponsor: Vanda Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 160 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 5
States / cities: Newport Beach, California • Andover, Massachusetts • Shelby, North Carolina + 2 more

Conditions: Diabetes Mellitus Type 2
Interventions: Placebo, aleglitazar; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 23
States / cities: Chino, California • Los Angeles, California • Santa Ana, California + 20 more

Conditions: Pediatric Cancer
Interventions: Cancer Care Companion; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Hemoglobin
Interventions: Radical-7 Noninvasive Hgb Monitor; Device
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Nebivolol, atenolol, placebo; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 76 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Prostate Hyperplasia
Interventions: Single Port Robotic Surgery, Laser Surgery; Procedure
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 88 Years · Male only
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Trauma, Pain
Interventions: intravenous fentanyl, intra-nasal fentanyl; Drug
Lead sponsor: Genesys; Other
Eligibility: 14 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Grand Blanc, Michigan

Search by objective public record fields.

Percutaneous Closure Versus Figure-of-eight Suture for Hemostasis in Leadless Pacemaker Implantation.

Celebrandome: Preliminary Study

A Study of Taspoglutide Versus Sitagliptin for the Treatment of Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin.

Dermatosis Papulosa Nigra

Efficacy and Safety of Indacaterol Plus Tiotropium Versus Tiotropium Alone in Patients With Chronic Obstructive Pulmonary Disease

Safety and Efficacy Study of EXC 001 to Improve the Appearance of Scars From Prior Breast Surgery

A Phase 2 Study to Evaluate Pregabalin and Acetaminophen Compared to Acetaminophen and Placebo in Subjects Undergoing Bunionectomy

Phase III Study Investigating Heart Failure and Cardiovascular Death With Baxdrostat in Combination With Dapagliflozin

INV-144 Versus Losartan in Hypertension and Type 2 Diabetes Mellitus Patients With Macroalbuminuria

Strong Families Start at Home/Familias Fuertes Comienzan en Casa

Evaluation of Enfilcon A Soft Contact Lens When Compared to Galyfilcon A Soft Contact Lens

A Comparison of Three Different Formulations of Prednisolone Acetate 1%

Study To Evaluate the Efficacy and Safety Of Bevacizumab, and Associated Biomarkers, In Combination With Paclitaxel Compared With Paclitaxel Plus Placebo as First-line Treatment Of Patients With Her2-Negative Metastatic Breast Cancer

Study to Compare Delafloxacin to Moxifloxacin for the Treatment of Adults With Community-acquired Bacterial Pneumonia

Laminaria Compared to Dilapan-S for Cervical Preparation Before Dilation and Evacuation at 18-24 Weeks of Gestation

Comparison of NN1250 With Insulin Glargine Plus Insulin Aspart With/Without Metformin and With/Without Pioglitazone in Type 2 Diabetes

Clinical Equivalence Study of Fluticasone Propionate Nasal Spray, 50 mcg/Actuation vs. Flonase in Allergic Rhinitis Patients

An Eight-Week Study to Evaluate the Safety and Efficacy of VSJ-110 Compared to Placebo in the Treatment of Dry Eye

A Study of Aleglitazar in Patients With Type 2 Diabetes Mellitus Who Have Not Previously Received Anti-Hyperglycemic Therapy

Cancer Care Companion

Noninvasive Hemoglobin Monitor in the ER

A Study Examining the Effects of Nebivolol Compared to Atenolol on Endothelial Function

Prostate Single Port & Laser Enucleation Comparison Trial

Intranasal Fentanyl for Pain Management